Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood pressure cuff trick could shield the heart in kidney disease

NCT ID NCT07746102

Disease control Sponsor: Medical University of Lodz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests whether repeated, brief periods of reduced blood flow to the leg—created by inflating a blood pressure cuff—can improve blood pressure, heart rate, and markers of inflammation in people with chronic kidney disease. The procedure, called ischemic preconditioning, is thought to trigger the body's own protective mechanisms against future injury. Over three days, participants will undergo four 5-minute cycles of cuff inflation and deflation, with blood and vital signs measured before and after. The goal is to see if this simple, non-drug intervention can offer cardiovascular benefits in this high-risk population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Repeated ischemic preconditioning episodes using a blood pressure cuff
What this could lead to
If effective, this simple, drug-free technique could offer a way to protect the heart and blood vessels in people with chronic kidney disease, potentially reducing cardiovascular risk.
What could go wrong
This is a small, early-stage study, so results may not be conclusive. The technique may not produce significant benefits, and there is a small risk of discomfort or injury from the cuff inflation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * obtaining the patient's voluntary, informed consent to participate in the experiment, * chronic kidney disease in stages G1-G5, * women and men over 18 years of age. * failure to meet the qualification criteria for participation in the study, * consciousness disorders, * heart failure (NYHA IV), * severe anemia (Hb concentration\<8g/dL), * features of muscle cell damage (e.g. rhabdomyolysis), * peripheral circulation disorders, peripheral vascular diseases. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood pressure disorders Chronic kidney disease Hemodialysis Inflammation Ischemia preconditioning

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical University of Lodzi

    RECRUITING

    Lodz, 90-213, Poland

  • Medical University of Lodzi

    RECRUITING

    Lodz, 92-219, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.